Korsana Biosciences, Inc. Common Stock
KRSA
58 hedge funds and large institutions have $75.8M invested in Korsana Biosciences, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 22 reducing their positions, and 14 closing their positions.
249% more call options, than puts
Call options by funds: $1.59M | Put options by funds: $456K
3.85% less ownership
Funds ownership: 60.9% → 57.05% (-3.9%)
11% less funds holding
Funds holding: 65 → 58 (-7)
21% less capital invested
Capital invested by funds: $96M → $75.8M (-$20.2M)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
45% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
+$174K |
| 2 |
Two Sigma Advisers
New York
|
+$150K |
| 3 |
Two Sigma Investments
New York
|
+$111K |
| 4 |
Franklin Resources
San Mateo,
California
|
+$54.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$49.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
E
Ergoteles
New York
|
-$375K |
| 2 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$332K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$257K |
| 4 |
HF
HRT Financial
New York
|
-$254K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$113K |
KRSA Hedge Fund Activity: Q3 2021 in Review
58 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q3 2021, worth a combined $75.8M — down 21% from $96M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of KRSA and 9 opened new positions — a net loss of 5 holders — while 22 trimmed existing stakes and 12 added.
The largest buyer was Eversept Partners, opening a new position worth an estimated $174K. The largest seller was Ergoteles, exiting entirely with an estimated $375K sold.
- 58 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q3 2021, down from 65 in Q2 2021.
- Funds reported $75.8M of Korsana Biosciences, Inc. Common Stock stock for Q3 2021, down 21% quarter-over-quarter.
- 9 funds opened new Korsana Biosciences, Inc. Common Stock positions in Q3 2021 and 14 closed out, a net change of -5 holders.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q3 2021 was Eversept Partners, an estimated $174K added.
- The largest Korsana Biosciences, Inc. Common Stock seller in Q3 2021 was Ergoteles, an estimated $375K sold.
Based on aggregated 13F filings for Q3 2021.